Overall, the health system, which is the largest hospital operator in the U.S., had a strong first quarter in 2024 with $1.8 in net income, an increase from $1.5 billion during the same period in 2023.
Below are 7 HCA executives’ stock transaction activities since May 2, according to the health system’s Securities and Exchange Commission reports:
1. Kathleen Whalen, senior vice president and chief ethics and compliance officer, sold 3,204 shares on May 16 for a market value of $1,045,465.
2. Kathryn Torres, senior vice president of payer contracting and alignment, sold 1,863 shares on May 15 for a total of $607,673.
3. Jeffrey Cohen, senior vice president of government relations, sold 1,650 of company stock for $516,450 on May 9.
4. Michael Cuffe, MD, executive vice president and chief clinical officer, sold 6,311 shares of HCA on May 9 for $1,999,824.
5. Bill Rutherford, sold 15,000 shares May 7 for $4,670,372. Mr. Rutherford retired as HCA’s CFO May 1. He was succeeded by Mike Marks, HCA’s former senior vice president of finance.
6. Dr. Cuffe sold an additional 1,600 shares of the company May 6 for $494,400.
7. On May 2, Ms. Torres sold another 1,863 in stock for $581,256.
An HCA spokesperson did not have an immediate comment for Becker’s regarding the recent executive stock transactions.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
